Butyrate-Producing Clostridium butyricum: A Direct Interactor with Colorectal Cancer Cells that Reverses Immune Suppression and Enhances Checkpoint Inhibitor Efficacy
Posted inClinical Updates Family Medicine & Nutrition Gastroenterology news Oncology Specialties

Butyrate-Producing Clostridium butyricum: A Direct Interactor with Colorectal Cancer Cells that Reverses Immune Suppression and Enhances Checkpoint Inhibitor Efficacy

Recent research uncovers that the probiotic Clostridium butyricum directly interacts with colorectal cancer cells to inhibit immune suppression via the secD-GRP78 axis, restoring CD8+ T cell antitumor function and enhancing PD-1 inhibitor therapy.
Predictive Factors for Diabetes Outcomes One Year After Total Pancreatectomy with Islet Autotransplantation: Insights from a Large Multicenter Study
Posted inClinical Updates Diabetes & Endocrinology General Surgery Specialties

Predictive Factors for Diabetes Outcomes One Year After Total Pancreatectomy with Islet Autotransplantation: Insights from a Large Multicenter Study

This multicenter study identifies key predictors of diabetes outcomes one year after total pancreatectomy with islet autotransplantation, highlighting the importance of preoperative glycemic control and age in achieving insulin independence and maintaining islet graft function.
Advancing Radiotherapy in High-Grade Glioma: Targeted Volume Reduction with Hypofractionated Simultaneous Boost IMRT
Posted inClinical Updates Oncology Radiology Specialties

Advancing Radiotherapy in High-Grade Glioma: Targeted Volume Reduction with Hypofractionated Simultaneous Boost IMRT

A randomized trial demonstrates that modified target delineation integrating multimodal MRI and white matter tractography with moderately hypofractionated radiotherapy achieves comparable survival outcomes to standard IMRT while reducing irradiation volumes in high-grade glioma patients.
Comparative Efficacy of Induction-Concurrent Versus Concurrent-Adjuvant Chemoradiotherapy in High-Risk N2-N3 Nasopharyngeal Carcinoma: Insights from a Phase 3 Randomized Trial
Posted inOncology Radiology Specialties

Comparative Efficacy of Induction-Concurrent Versus Concurrent-Adjuvant Chemoradiotherapy in High-Risk N2-N3 Nasopharyngeal Carcinoma: Insights from a Phase 3 Randomized Trial

A phase 3 trial showed no significant difference in 3-year progression-free survival between induction-concurrent and concurrent-adjuvant chemoradiotherapy in treating high-risk N2-N3 nasopharyngeal carcinoma, with both regimens exhibiting manageable safety profiles.